Project Grant R01CA300691
Award Date
4/14/25
Completion Date
3/31/30
Dollars Obligated
$781K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) for $460,977 aims to identify novel "chemo-neoepitopes" (CNEs) that can be used as immunogens to generate antitumor CD8+ T cell responses for the treatment of triple-negative breast cancer (TNBC). The project will focus on leveraging chemotherapy-induced changes in splicing and intron retention to generate cancer-specific, non-mutated neoantigens that can potentially be recognized by...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a CD4 TCR-engineered T cell immunotherapy for the treatment of triple-negative breast cancer (TNBC). The awardee, Immunova Therapeutics LLC, will generate a GMP-grade master cell bank and viral particles for the IMT-422 (CD4 TCR-STEM T cells) product, and evaluate its pharmacokinetics, biodistribution, and toxicity in preclinical studies. The goal is to...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
This Project Grant award for $215,311 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports preclinical research on antibody-drug conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The University of Texas Health Science Center at Houston (UTHealth) will evaluate the safety and efficacy of novel GPR56-targeted ADCs, both as a single therapy and in combination with PARP inhibitors, in TNBC cell lines and...
The National Cancer Institute (NCI) awarded a $661,072 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Northwestern University to develop a novel therapy with dual immuno-oncology targeting capabilities for the treatment of triple negative breast cancer. The project aims to conduct IND-enabling studies for a first-in-class USP22-specific small molecule inhibitor that can impair cancer cell growth, stemness, and boost anti-tumor immunity. This research aligns with the NCI's goals to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $512,582 to the University of Massachusetts Medical School over a 5-year period beginning June 1, 2024. The goal of this research is to develop a novel therapeutic approach for overcoming resistance to radiation therapy in triple negative breast cancer (TNBC). The project will investigate the mechanism by which vascular endothelial growth factor (VEGF) signaling through neuropilin-2...
This $125,000 Project Grant awarded by the National Institute of General Medical Sciences (NIGMS) under CFDA 93.859 Biomedical Research and Research Training program supports research to characterize the tumor immune microenvironment (TIME) and metastatic progression in triple negative breast cancer (TNBC). The award to Baylor College of Medicine aims to spatially profile the TIME of lung and liver metastases following treatment with anti-CSF1R, chemotherapy, and anti-PD1 therapy. The goal is to...
This federal Project Grant award, valued at $542,721.00 and awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), supports research to develop a ferritin-degrading proteolysis targeting chimera (DEFER) molecule and a platelet-based delivery system to inhibit the growth of triple-negative breast cancer (TNBC). The key products and services to be...
The federal Project Grant award R01CA280194 provides funding of $622,329 to Virginia Commonwealth University (VCU) from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) to develop an effective small molecule inhibitor (PDZ1I) that can simultaneously inhibit the dissemination and growth/survival of progressive triple-negative breast cancer (TNBC). The research aims to: 1) Formulate PDZ1I for clinical applications and characterize non-cell-autonomous mechanisms by...
This federal Project Grant award of $545,983 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Northwestern University to identify molecular regulators of interactions between circulating tumor cells (CTCs) and the host immune system, with a focus on the aggressive triple-negative breast cancer (TNBC) subtype. The key objectives are to: 1) Determine the clinical relevance of the PB2 signaling pathway in TNBC, 2) Elucidate the molecular mechanisms...